Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open Label Study to Evaluate the Long-term Safety and Efficacy of Odevixibat (A4250) in Patients With Alagille Syndrome (ASSERT-EXT)

NCT05035030 is registered in ClinicalTrials.gov with Albireo, an Ipsen Company as lead sponsor.

NCT NCT05035030
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05035030 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open Label Study to Evaluate the Long-term Safety and Efficacy of Odevixibat (A4250) in Patients With Alagille Syndrome (ASSERT-EXT)
Lead sponsor
Albireo, an Ipsen Company
Phase
Phase 3
Overall status
Active, not recruiting
Start date
September 3, 2021
Completion date
December 31, 2026
Enrollment
62 (actual)
Sites
35

Conditions

As the registry lists them; a condition with its own page is linked.

alagille syndrome